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(http://creativecommoment of Alzheimer’s disease (AD). Thus, lipid metabolites appear to be highly useful as diagnostic
substrates for the diagnosis of AD and mild cognitive impairment (MCI) in plasma.
Methods: We analyzed plasma samples from controls (n 5 35), MCI (n 5 33), and AD patients
(n 5 43) using the AbsoluteIDQ p180 Kit (Biocrates Life Sciences), which included quantitative
analysis of 40 acylcarnitines, 21 amino acids, 19 biogenic amines, 15 sphingolipids, 90 glycerophos-
pholipids, and sum of hexoses.
Results: We found that individual lipid metabolites can differentiate controls fromMCI and ADwith
relevant significance. However, the ratio between PC aa C34:4 and lysoPC a C18:2 differentiates con-
trols from MCI (P 5 .0000007) and from AD (P 5 .0000009) with greater significance.
Conclusions: The results provide evidence that the ratio of these two lipid metabolites is useful for
diagnosing MCI and AD with an accuracy of 82%–85%.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Keywords: Alzheimer’s disease; Mild cognitive impairment; Diagnosis; Plasma; Metabolomics1. Introduction
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disease of the brain characterized by extracellular
b-amyloid plaques, intraneuronal neurofibrillary tau tangles,
inflammation and glial responses, vascular dysfunction,
cholinergic neurodegeneration, and synapse loss that
directly correlates with cognitive decline and memory loss.
The causes of AD are not known but the most prominent hy-
pothesis is the b-amyloid cascade hypothesis [1]. However,
dysfunctions in tau phosphorylation may also play a role in-M. have no conflict of interest. K.K., G.D., and T.K.
rates.
thor. Tel.: 143-512-504-23712; Fax: 143-512-504-
ristian.humpel@i-med.ac.at
16/j.dadm.2015.05.003
he Authors. Published by Elsevier Inc. on behalf of the Alzh
ns.org/licenses/by/4.0/).dependent of b-amyloid [2] but recent evidence indicates
that both proteins interact [3]. More and more clinical and
basic data show that a vascular risk factors may play a role
in the development of AD [4] and that a dysfunction of the
blood-brain barrier may also account for dysregulated
clearing of b-amyloid from the brain [5].
The diagnosis of possible or probable AD is made on the
basis of a time-consuming psychological test and clinical ex-
amination by excluding other psychiatric and neurologic dis-
eases. Brain imaging and the analysis of cerebrospinal fluid
(CSF) samples are important but expensive tools for veri-
fying the diagnosis. Due to the invasive nature of CSF
collection, blood biomarkers need to be found to allow
screening and multiple analyses of patients, especially those
with mild cognitive impairment (MCI). There is more and
more evidence to show that a single biomarker cannot yield
enough sensitivity and specificity to diagnose AD [6,7].eimer’s Association. This is an open access article under the CC BY license
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specific signature are state-of-the-art.
In 2007, Ray et al. [8] claimed to diagnose AD from
plasma using a panel of 18 biomarkers. However, several
groups including ours failed to reproduce this finding
[9,10]. Recently, Mapstone et al. [11] demonstrated that a
set of 10 endogenous lipids from peripheral blood can pre-
dict phenoconversion to either amnestic MCI or AD within
a 2–3 year time frame with over 90% accuracy. In fact, there
are clear indications that metabolic processes are linked to
the development and pathology of AD [12,13] and
metabolomics is turning out to be a novel fascinating
method for analyzing a large panel of lipid metabolites
[14]. Two recent articles clearly demonstrate that plasma lip-
idomics is associated with AD [15] and that a blood-based
7-metabolite signature may diagnose early AD [16].
The aim of the present study was to analyze the metabo-
lome in plasma samples of controls, MCI, and AD patients.
We quantitatively analyzed 40 acylcarnitine metabolites, 21
amino acids, 19 biogenic amines, 15 sphingolipids, and 90
glycerophospholipids using the AbsoluteIDQ p180 Kit (Bio-
crates Life Sciences AG, Innsbruck, Austria). We here show
that several lipids are altered in MCI and AD EDTA plasma
and that two lipids or their ratio provide a potent biomarker
for distinguishing MCI and AD from controls.2. Methods
2.1. Patients
A total of 111 samples (healthy controls, AD, and MCI)
were included in this study during the sample collection
period 2004–2012. All patients were.70 years and were re-
cruited from thememory clinics at the Department of Psychi-
atry of Innsbruck Medical University and Hall in Tirol State
Hospital, both in Austria. Healthy subjects, mainly healthy
caregivers and volunteers without any cognitive impairment,
were also recruited at these sites. Psychiatrists clinically
examined all subjects, performed a standardized psychiatric
and neurologic examination, reviewed medical records, and
all subjects underwent a neuropsychological assessment
(mini mental state examination [MMSE] and geriatric
depression scale [GDS]). Exclusion criteria for healthy sub-
jects and patients suffering from MCI or AD included other
psychiatric or neurologic diseases or diseases including can-
cer, vascular diseases, or other diseaseswith clinically signif-
icant hepatic, renal, pulmonary, metabolic or endocrine
disturbances, and inflammation. Participants underwent
continuous statin or ezetimibe treatment for at least 3 months
before study entry. No patient had a cholesterol level
.240 mg/dL that was not treated with a statin or ezetimibe.
The procedure for diagnosis has been described by us in
detail elsewhere [9,17]. The study was approved by the
Local Ethics Committee of Innsbruck Medical University
and was performed in accordance with the Helsinki
Declaration. All subjects gave written informed consent.2.2. Blood collection
Blood samples were taken between 9:30 and 11:00
AM. Participants had a fasting time ranging from 1 to 3
hours. Breakfast foods taken by the participants were
not noted. After a patient was assigned to a group,
10 mL of EDTA blood was collected and processed.
The samples were centrifuged (400 ! g, 30 min), and
the upper plasma phase was immediately frozen at
280C. Blood processing time was 4.3 6 0.2 hours; the
blood from 26% of the patients was processed the next
day. Thus, mean processing time was 10.3 6 1.8 hours
(controls), 8.8 6 1.4 hours (MCI), and 10.3 6 1.5 hours
(AD). Processing times did not differ between groups.
To test the stability of the metabolites, EDTA blood was
taken from non–cognitively impaired volunteers and AD
patients and processed immediately (t 5 0) or it was
left at room temperature for 1, 2, or 3 days and then pro-
cessed. To test stability over 2 years at 220C, blood was
taken from a volunteer, processed and analyzed immedi-
ately or stored at 220C for 2 years, and then analyzed.
2.3. Metabolomic analysis
The endogenous metabolites were analyzed with a tar-
geted quantitative and quality controlled metabolomics
approach using the AbsoluteIDQ p180 Kit (Biocrates Life
Science AG) as described recently by us [18]. This validated
assay allows the comprehensive identification and the quan-
tification of 186 endogenous metabolites including 21 amino
acids, 19 biogenic amine, 40 acylcarnitines, 76 phosphatidyl-
cholines (PCs), 14 lysophosphatidylcholines (lysoPCs), 15
sphingomyelins, and sumof hexoses. Analyzed glycerophos-
pholipids are differentiated according to the presence of ester
and ether bonds in the glycerol moiety. The “aa” indicates
that fatty acids are at the sn-1 and the sn-2 position bound
to the glycerol backbone via ester bonds, whereas “ae” de-
notes that fatty acid at the sn-1 position is bound via ether
bond. Total number of carbon atoms and double bonds pre-
sent in lipid fatty acid chains are denoted as “C x:y,” where
x indicates the number of carbons and y the number of double
bonds. Sample preparation was performed according to the
usermanual. Sampleswere randomized, andmultiple quality
control samples were included in themeasurement sequence.
Intra-assay variationwas 3.86 0.8% (n5 32) and inter-assay
variation 4.4 6 1.1% (n5 32).
2.4. Statistical analysis
Plasma metabolites were checked for deviations from a
normal distribution using the Shapiro-Wilk test [19]. Metab-
olites with a nonnormal distribution were log-transformed
before analysis. One-way analysis of variance was used to
compare the three diagnostic groups (healthy controls,
MCI, and AD) with respect to the plasma levels. Post hoc
pairwise comparisons were performed with Fisher’s least-
significant difference method. In the case of the three groups,
Table 1
Participant characteristics
Characteristics Controls MCI AD
n 35 33 43
Male (%) 37.1 45.4 32.5
Age (y) 77 6 7 75 6 7 (NS) 81 6 5*
Blood processing (h) 10.3 6 1.8 8.8 6 1.4 (NS) 10.3 6 1.5 (NS)
MMSE 29.0 6 1.2 27.3 6 1.2* 20.6 6 4.4***
GDS 6.8 6 6.7 5.6 6 5.3 (NS) 7.4 6 5.7 (NS)
Abbreviations: MCI, mild cognitive impairment; AD, Alzheimer’s dis-
ease; NS, not significant;MMSE,mini mental state examination; GDS, geri-
atric depression scale; SD, standard deviation; ANOVA, analysis of
variance.
NOTE. The Table gives the demographic data of patients who partici-
pated in this study. Values are given as mean 6 SD. Statistical analysis
was performed by one-way ANOVA with a subsequent Dunnett post hoc
test (*P, .05; ***P, .001; P values refer to the differences between clin-
ical subgroups [MCI or AD] and controls).
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multiple testing [20]. For all markers, significance was
adjusted for multiple testing using the Bonferroni method,
dividing the usual significance level (a5 0.05) by the num-
ber of tests performed (acorrected 5 0.05/183 5 0.0002732).
Performance of each metabolite and metabolite ratios as po-
tential biomarker was evaluated with receiver operating
characteristic (ROC) analysis. All lipid metabolites
including the ratios were entered in a ROC analysis to obtain
estimates of the sensitivity and specificity and of the area un-
der the ROC curve (AUC). Optimal cutoff levels were deter-
mined such that the sum of sensitivity and specificity was
maximized. Bias-corrected estimates of sensitivity and spec-
ificity were obtained using leave-one-out cross-validation
[21]. Calculation of 95% confidence intervals for cutoff
levels was based on confidence limits for the ED50 as pro-
vided in the probit regression routine in SPSS, version 22.
Moreover, positive and negative predictive values were
calculated based on the prevalence of MCI and AD as given
in the sample investigated (this was representative for the
two participating memory clinics). The Fagan nomogram
was used to provide a graphical presentation of pretest and
posttest probabilities for MCI or AD [22]; (http://araw.
mede.uic.edu/cgi-bin/testcalc.pl).3. Results
3.1. Screening of metabolites
The present study investigated 43 AD, 33 MCI, and 35
control plasma samples with a targeted quantitative me-
tabolomics approach (Supplementary Table 1). MCI pa-
tients did not differ in age, gender, or GDS but had
slightly reduced MMSE scores as compared with those
of controls (Table 1). AD patients were slightly older
(P , .05) and had highly significantly reduced MMSE
scores (Table 1). Statistical analysis identified significant
alteration in glycerophospholipid levels. The levels of
five phosphatidylcholines (PC aa C34:4, C36:6, C38:3,
C40:5, and C40:6) were lower and levels of two lysoPCs
(lysoPC a C18:1 and lysoPC a C18:2) were higher in MCI
and AD plasma samples than in controls (Table 2). The
metabolites with best performance for differentiating
AD and MCI patients from controls were PC aa C34:4
(AUC 0.76) and PC aa C40:5 (AUC 0.77). Adjustment
for age by analysis of covariance had little effect on the
results and left the P values in Table 2 almost unchanged.
Two plasma amino acids were altered in AD as compared
with those of controls (glycine P 5 .017 and valine
P 5 .059) but these data should be considered with care
because amino acids are markedly altered by fasting
(see Discussion in the following).
3.2. Ratio of lipid metabolites
When the ratios between PC aa C34:4 or C36:5 or
C36:6 and lysoPC a C18:1 or C18:2 were calculated, thesignificance to differentiate controls from MCI and AD pa-
tients was dramatically higher (Table 2). Our data show
that the ratio between PC aa C34:4 and lysoPC a C18:2
highly significantly differentiates controls from MCI
patients (P 5 .0000007; AUC under ROC 5 0.85) and con-
trols from AD patients (P 5 .0000009; AUC under
ROC 5 0.82; Table 2; Fig. 1). More detailed analyses
reveal that the mentioned ratio shows good performance
in terms of sensitivity, specificity, and both positive and
negative predictive value for differentiating MCI patients
from controls (all values .0.8) and satisfactory accuracy
for distinguishing AD patients from controls (all values
.0.7; Table 3). A graphical presentation of pretest and
posttest probabilities by Fagan nomogram of MCI and
AD is given in Fig. 2. The ratios between PC aa C34:4/ly-
soPC a C18:1 and PC aa C36:6/lysoPC a C18:1 and PC aa
C36:6/lysoPC a C18:2 were similar but not as potent. In no
case did the ratios differentiate MCI from AD patients
(Table 2).
3.3. Stability of the lipids
To test the lipid stability during the processing of blood
samples, we analyzed our two best lipids in blood from a
cognitively nonimpaired volunteer (Table 4A) and a severe
AD patient (Table 4B). Our data show that the plasma levels
of lysoPC a C18:2 were significantly higher in blood sam-
ples after storage for 24 hours at room temperature, whereas
plasma levels of PC aa C34:4 were significantly lower in
blood samples after storage for 48 hours at room tempera-
ture. However, more importantly, the ratio between these
two lipids was significantly lower after storage of blood sam-
ples for 24 hours at room temperature. Thus, these data
clearly demonstrate the instability of both lipids when blood
samples are stored for a prolonged time at room temperature.
Consequently, it was important to test the stability of these
two metabolites in frozen samples. Our results from long-
term stability (Table 4C) show that lipids are stable at
Table 2
Plasma levels of the most important metabolites and metabolite ratios altered in mild cognitive impairment (MCI) and Alzheimer (AD) patients
Metabolites and metabolite ratios
Plasma levels P values ROC (AUC)
CO MCI AD CO versus MCI CO versus AD MCI versus AD MCI AD
Metabolites
lysoPC a C18:1 23 6 6 27 6 8 28 6 8 NS .002 NS — 0.71
lysoPC a C18:2 28 6 9 38 6 15 34 6 10 .0005 NS NS 0.78 —
PC aa C34:4 2.5 6 0.6 2 6 0.4 1.9 6 0.6 .0005 .00005* NS 0.73 0.76
PC aa C36:6 1.3 6 0.4 1 6 0.3 1 6 0.4 .0007 .0008 NS 0.7 0.71
PC aa C38:3 56 6 13 44 6 10 51 6 11 .00005* NS NS 0.78 —
PC aa C40:5 13 6 3 10 6 2 11 6 2 .00002* .003 NS 0.77 0.67
PC aa C40:6 33 6 12 25 6 6 28 6 10 .002 NS NS 0.7 —
Metabolite ratios
PC aa C34:4/lysoPC a C18:1 0.11 6 0.04 0.08 6 0.03 0.07 6 0.03 .00003 .0000002 NS 0.8 0.83
PC aa C34:4/lysoPC a C18:2 0.10 6 0.04 0.06 6 0.02 0.06 6 0.02 .0000007 .0000009 NS 0.85 0.82
PC aa C36:5/lysoPC a C18:2 1.4 6 0.8 0.9 6 0.5 0.9 6 0.4 .0005y .0002y NS 0.73 0.74
PC aa C36:6/lysoPC a C18:1 0.06 6 0.03 0.04 6 0.02 0.04 6 0.01 .00004 .000001 NS 0.75 0.8
PC aa C36:6/lysoPC a C18:2 0.05 6 0.02 0.03 6 0.02 0.03 6 0.01 .000001 .000003 NS 0.83 0.79
Abbreviations: CO, control; MCI, mild cognitive impairment; AD, Alzheimer’s disease; ROC, receiver operating characteristic; AUC, area under the ROC
curve; SD, standard deviation; NS, not significant; ANOVA, analysis of variance; LSD, least-significant difference.
NOTE. Values are given as mean6 SD (in mM for metabolites). The number of patients was 35 (controls), 33 (MCI), and 43 (AD). Samples were statistically
analyzed using ANOVA and Fisher’s LSD post hoc test as well as the ROC curve. The P values and area under the ROC curve (AUC) are given. For all other
parameters, significance was retained after adjustment for multiple testing using the Bonferroni method.
*For these markers, significancewas retained after adjustment for multiple testing by means of the Bonferroni method: P, .05/1835 .0002732. For all other
parameters, significance was not retained after adjustment for multiple testing using the Bonferroni method.
yFor these markers, significance was “not” retained after adjustment for multiple testing by means of the Bonferroni method, i.e., P . .0002732.
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samples should be processed and frozen as soon as possible
after sampling. Otherwise, metabolite instability might
cause a false-negative diagnosis.4. Discussion
In the present study, we screened 186 metabolites in
plasma from control, MCI, and AD patients. Our data
show that two lipids significantly differentiate MCI and
AD patients from healthy controls, and the ratio is even
more significant and may provide a novel biomarker. Both
lipids display instability in whole blood stored for 24 hours
at room temperature but are stable in frozen plasma for up to
2 years.
A decrease in PCs and lysoPCs in patients with AD has
been reported before in peripheral blood samples [23–25],
postmortem brain samples [26], and animal models
[26,27]. Mapstone et al. [11] demonstrated that a set of 10
lipids (C3, lysoPC a C18:2, PC aa C36:6, C16:1- OH, PC
aa C38:0, PC aa C38:6, PC aa C40:1, PC aa C40:2, PC aa
C40:6, and PC ae C40:6) from peripheral blood can be
used to predict phenoconversion from control to either
MCI or AD with over 90% accuracy. All these metabolites
were also measured with the same technological platform
in our sample set. As a matter of fact, three of them, PC aa
C34:4, PC aa C38:3 and PC aa C40:5, retained significant af-
ter post-Bonferroni correction for multiple testing. This un-
derlines the relevance of PCs in AD pathophysiology as
previously indicated [11,15]. The reduced levels of PCs
might be linked with aberrant activity of phospholipase A2(PLA2). PLA2 are enzymes that catalyse cleavage of fatty
acids from the sn-2 position of phospholipids, producing
free fatty acids and lysoPCs. It has been reported that b-am-
yloid42 peptides (that aggregate in the AD brain) increase
PLA2 activity [28]. In fact, Hicks et al. [28] demonstrated
that PLA2 is involved in the mechanism underlying the effect
of b-amyloid42 oligomers on cell membrane phase proper-
ties. PLA2 implications in AD have been described compre-
hensively elsewhere [29].
Some studies also reported altered lysoPC levels in AD
patient plasma [25,30], CSF [31], and in total postmortem
AD brains [26]. LysoPCs are the product of PLA2 catalysed
reaction and are believed to be rapidly acylated with acetyl-
CoA to maintain normal neural membrane composition. We
hypothesize that aberrant PLA2 activity could also be the
cause of altered levels of lysoPC, caused by a decrease in
PC to lysoPC ratios in MCI and AD patients. Indeed, an in-
crease in lysoPC levels has been observed in transgenic APP/
tau mice [26,27]. Also, several lysoPC species (including
lysoPC a C18:1 and lysoPC a C18:2) have been reported
to be increased in frontal cortex of postmortem AD brains
[26]. Nevertheless, it has been recognized that lysoPCs are
not only glycerophospholipid metabolism intermediates
but also serve as mediators in multiple neuronal pathways
[32]. Moreover, it has been suggested that several plasma ly-
soPC species are inhibitors of secreted PLA2 enzyme activ-
ity [33].
This study entails several limitations: (1) A main lim-
itation of the present study is the small size of the sam-
ples. This study should therefore be followed up by
large-scale multicenter studies that should also include
Fig. 1. Raw values and ROC curves of the metabolite ratio with the highest statistical significance in MCI (A) and AD (B) patients as compared with those of
controls. Abbreviations: MCI, mild cognitive impairment; AUC, area under the ROC curve; AD, Alzheimer’s disease; ROC, receiver operating characteristic.
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frontotemporal lobe dementia. (2) Another limitation is
that the patients were not followed up to determine the
significance of prognosis of conversion to MCI or AD,
as shown in the Mapstone work [11]. (3) There was a
small but significant difference in age between AD pa-
tients and patients with MCI and healthy subjects. Howev-
er, when adjusting for age by analyzing covariance, P
values for differences between the three groups remained
virtually unchanged. Nevertheless, further data with age-
matched groups are necessary to ensure that age is not a
confounder responsible for the differences between con-
trol subjects and AD patients [34]. (4) In this study, we
used EDTA as an anticoagulant. It would be interesting
to test if there are differences in serum, EDTA plasma, cit-rate plasma, or heparin plasma [35,36]. (5) We clearly
show that the lipids were not stable in whole blood
samples stored at room temperature for 24 hours. Thus,
future studies will have to have a processing time of
3–4 hours. Our data clearly show that prolonged storage
of blood causes false-negative results. Thus, a detailed ex-
amination of all metabolites recommended for diagnosis
is essential [37]. (6) It has been recognized that nutritional
status can influence blood levels of several metabolite
classes, especially amino acids and acylcarnitines [38],
and should be considered when evaluating metabolomics
data. Therefore, some authors recommend fasting before
blood collection. However, to our best knowledge, the
most important metabolites reported in this study are
not significantly influenced by fasting or non-fasting
Table 3
Prediction of MCI and dementia by the ratio between PC aa C34:4 and lysoPC a C18:2: AUC of ROC curve, optimal cutoff value, sensitivity, specificity,
positive, and negative predictive value
Measure
MCI versus control AD versus control
Estimate 95% CI Estimate 95% CI
Area under ROC curve (unbiased estimate)* 0.853 0.743–0.926 0.823 0.717–0.898
Optimal cutoff value for the ratio 0.064y 0.052–0.076 0.0715z 0.060–0.085
Sensitivity (bias-corrected)x 0.813 0.636–0.928 0.744 0.588–0.865
Specificity (bias-corrected)x 0.857 0.702–0.940 0.771 0.599–0.895
Positive predictive value (bias-corrected)x 0.839 0.667–0.934 0.800 0.650–0.898
Negative predictive value (bias-corrected)x 0.833 0.677–0.925 0.711 0.551–0.831
Abbreviations: MCI, mild cognitive impairment; AUC, area under the ROC curve; ROC, receiver operating characteristic; AD, Alzheimer’s disease; CI, con-
fidence interval.
*As all subjects included had verified disease status, AUC estimation was unbiased.
yA subject was classified as MCI if the ratio between PC aa C34:4 and lysoPC a C18:2 was ,0.064, otherwise as cognitively intact.
zA subject was classified as AD if the ratio between PC aa C34:4 and lysoPC a C18:2 was ,0.0715, otherwise as cognitively intact.
xBias-corrected estimates were derived by cross-validation (leave-one-out method).
K. Klavins et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 295-302300[38]. Nevertheless, more detailed investigation will be
necessary in further studies. (7) The ethnicity of patients
may have an effect on metabolism; the present study
used samples from a group of persons of the same
ethnicity. (8) Preanalytical variations may have a signifi-
cant impact on blood metabolome [39,40]. Therefore, itFig. 2. Fagan nomogram showing pretest and posttest probabilities of developing
subjects with negative test result). Abbreviations: MCI, mild cognitive impairmenis of utmost importance to consider these variances as
they might cause misleading data interpretations. All our
assays were analyzed under well-controlled conditions
with an intra- and inter-assay variation of ,5%. Taking
into account all previously described limitations, it is
highly recommended that blood collection and processingMCI (A) or AD (B) (blue line: subjects with positive test result, red line:
t; AD, Alzheimer’s disease.
Table 4
Stability of the lipid metabolites
Healthy controls,
Alzheimer patients,
and stability PC aa C34:4 lysoPC a C18:2 Ratio
A
Day 0 100 6 1 100 6 1 100 6 1
Day 1 91 6 2 NS 125 6 2* 80 6 1***
Day 2 87 6 3** 136 6 4*** 70 6 4***
Day 3 83 6 1*** 145 6 4*** 60 6 3***
B
Day 0 100 6 5 100 6 7 100 6 3
Day 1 80 6 6* 120 6 7* 64 6 6***
C
Fresh 100 6 7 100 6 6 100 6 5
2 y—20C 102 6 4 NS 105 6 6 NS 98 6 5 NS
Abbreviations: NS, not significant; SEM, standard error of the mean; AN-
OVA, analysis of variance.
NOTE. Stability of plasma lipid metabolites in healthy controls (A) and
Alzheimer patients (B): Blood (4 ! 2 mL) was collected in EDTA tubes,
processed (centrifuged and stored at 280C) immediately, or after 1–2 or
3 d storage at room temperature. C: Stability at 220C: Blood was
collected, immediately processed, and analyzed the same day, or a plasma
aliquot was frozen at 220C and analyzed after 2 y. Values are given as
mean6 SEM% of control. Plasma was analyzed as described in quadrupli-
cate. Statistical analysis was performed by one-way ANOVAwith a subse-
quent Dunnett post hoc test (*P , .05; **P , .01; ***P , .001).
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article from the Alzheimer’s biomarkers standardization
initiative [41] describes in full detail recommended pa-
rameters for future standardization.
Taken together and in conclusion, we show that different
PC and lysoPC are altered in plasma of AD and MCI pa-
tients as compared with that of healthy controls. Our data
suggest that the ratio of PC aa C34:4 to lysoPC a C18:2,
representing the pathophysiological changes of PCs, might
be highly useful as a novel plasma biomarker for the diag-
nosis of early dementia. The biomarker analysis in blood
samples using a targeted metabolomics approach is quanti-
tative, quick, easy, and less expensive than other assays.
Further longitudinal studies and reproduction by at least
two other laboratories worldwide will be necessary to
introduce PC- and lysoPC-based metabolomic markers
into clinical routine.Acknowledgments
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1. Systematic review:We searched PubMed and Scopus
to identify research studies that investigate metabo-
lome changes in Alzheimer’s disease (AD). The rele-
vant citations are appropriately cited. References
cited in the identified studies were also consulted.
2. Interpretation: The present results show significant
changes in ratio of phosphatidylcholines to lysophos-
phatidylcholines in mild cognitive impairment and
AD patients that might be potentially used for diag-
nosis with an accuracy of 82%–85%.
3. Future directions: Future longitudinal studies with a
larger cohort need to be carried out to validate our
findings. Blood collection and processing should be
standardized.References
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